Risk of some cannibalisation between Wegovy, Saxenda. New study data shows sustained weight loss over 2 years. Novo will launch Wegovy in the U.S. on June 10 ...

Saxenda® (liraglutide) injection 3 mg becomes the first FDA-approved therapy to treat obesity in adolescents in more than a decade PLAINSBORO, N.J., Dec. 4, 2020 /PRNewswire/ -- Novo Nordisk ...

Eli Lilly’s stock wobbled after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy and Saxenda will become the preferred options ...

Novo presented top line data on a CVOT trial for liraglutide. Liraglutide is main ingredient in Victoza and Saxenda. Stock reacted well to news, but sales figures will tell the story. Novo Nordisk ...

In a new study published in the JAMA Network Open medical journal, Novo Nordisk A/S’s (NYSE:NVO) Saxenda (liraglutide), an earlier-generation weight loss drug, reveals significant declines in ...

Morgan Stanley (NYSE:MS) analysts raised their forecast for the global obesity market by over 40% in response to the supply shortages. Analysts now see the market hitting $77 billion in 2030, up from ...

For the study, researchers analyzed data on nearly 3,400 adults treated with either Ozempic or Saxenda between 2015 and 2022. ... The stock market is on a roll, ...